Commitments and Contingencies (Details) ₪ in Thousands, $ in Thousands |
1 Months Ended | 3 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Jan. 13, 2025
USD ($)
|
Dec. 18, 2024
USD ($)
|
Mar. 31, 2023
USD ($)
|
Mar. 31, 2023
ILS (₪)
|
Mar. 31, 2022
USD ($)
|
Mar. 31, 2022
ILS (₪)
|
May 31, 2021
USD ($)
|
Mar. 31, 2025
USD ($)
|
Mar. 31, 2025
ILS (₪)
|
|
| Commitments and Contingencies [Line Items] | |||||||||
| Upfront payment | $ 500 | ||||||||
| Payment from APT to oyster | $ 300 | $ 300 | |||||||
| Aggregate budget | $ 3,164 | ₪ 11,283 | $ 4,094 | ₪ 13,004 | |||||
| Fund approved budget | 30.00% | ||||||||
| Total grants approved | $ 9,353 | ₪ 32,068 | |||||||
| Royalties’ payments | 7,413 | ||||||||
| Contingent obligation | 8,403 | ||||||||
| Israel Innovation Authority [Member] | |||||||||
| Commitments and Contingencies [Line Items] | |||||||||
| Received amount | $ 395 | 1,365 | |||||||
| Minimum [Member] | |||||||||
| Commitments and Contingencies [Line Items] | |||||||||
| Royalties rate | 3.00% | ||||||||
| Maximum [Member] | |||||||||
| Commitments and Contingencies [Line Items] | |||||||||
| Royalties rate | 3.50% | ||||||||
| Cystic Fibrosis Product [Member] | |||||||||
| Commitments and Contingencies [Line Items] | |||||||||
| Received amount | $ 768 | 2,783 | |||||||
| Total grants approved | $ 8,003 | ₪ 27,423 | |||||||
| X | ||||||||||
- Definition Aggregate amount of budget. No definition available.
|
| X | ||||||||||
- Definition The fund approved budget. No definition available.
|
| X | ||||||||||
- Definition Oyster paid an upfront payment. No definition available.
|
| X | ||||||||||
- Definition Payment from APT to oyster. No definition available.
|
| X | ||||||||||
- Definition Pay based on royalties rate. No definition available.
|
| X | ||||||||||
- Definition Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of cash paid for royalties during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|